BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
57.35
-0.87 (-1.49%)
At close: Apr 17, 2026
SHA:688166 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 961.06 | 765.35 | 998.05 | 1,180 | 336.84 |
Trading Asset Securities | - | - | 50.62 | 50.12 | 0.76 |
Cash & Short-Term Investments | 961.06 | 765.35 | 1,049 | 1,230 | 337.6 |
Cash Growth | 25.57% | -27.02% | -14.78% | 264.48% | -35.02% |
Accounts Receivable | 330.02 | 339.5 | 308.88 | 307.47 | 373.85 |
Other Receivables | 9.13 | 6.66 | 19.91 | 18.78 | 3.75 |
Receivables | 339.14 | 346.17 | 328.79 | 326.25 | 377.59 |
Inventory | 364.25 | 364.61 | 344.63 | 280.35 | 200.06 |
Prepaid Expenses | - | - | 3.65 | 5.83 | 4.48 |
Other Current Assets | 124.04 | 164.14 | 114 | 95.39 | 73.27 |
Total Current Assets | 1,789 | 1,640 | 1,840 | 1,938 | 993.01 |
Property, Plant & Equipment | 2,752 | 2,705 | 2,489 | 2,076 | 1,378 |
Long-Term Investments | 671.08 | 437.06 | 425.86 | 399.33 | 348.28 |
Goodwill | - | 3.12 | 7.5 | 7.5 | 7.5 |
Other Intangible Assets | 79.53 | 89.48 | 93.66 | 81.64 | 80.84 |
Long-Term Accounts Receivable | 4.1 | 2.1 | - | - | - |
Long-Term Deferred Tax Assets | 94.68 | 62.2 | 42.28 | 23.94 | 19.86 |
Long-Term Deferred Charges | 339.19 | 57.49 | 30.18 | 26.87 | 25.83 |
Other Long-Term Assets | 95.42 | 156.03 | 104.09 | 107.73 | 115.86 |
Total Assets | 5,825 | 5,153 | 5,032 | 4,661 | 2,970 |
Accounts Payable | 185.89 | 266 | 228.18 | 252.19 | 211.89 |
Accrued Expenses | 82.97 | 72.01 | 72.31 | 69.04 | 61.72 |
Short-Term Debt | 110.11 | 115.26 | 156.87 | 124.38 | 257.05 |
Current Portion of Long-Term Debt | 775.1 | 516.96 | 397.93 | 313.87 | 16.58 |
Current Portion of Leases | 8.83 | 13.69 | 16.1 | 1.34 | 9.87 |
Current Income Taxes Payable | 10.61 | 16.68 | 14.04 | 14.97 | 3.69 |
Current Unearned Revenue | 25.56 | 28.02 | 24 | 29.49 | 20.33 |
Other Current Liabilities | 81.23 | 23.76 | 12.81 | 6.26 | 1.93 |
Total Current Liabilities | 1,280 | 1,052 | 922.25 | 811.52 | 583.07 |
Long-Term Debt | 1,490 | 1,580 | 1,615 | 1,576 | 618.69 |
Long-Term Leases | 10.21 | 10.21 | 21.01 | 6.01 | 0.22 |
Long-Term Unearned Revenue | 167.58 | 84.71 | 26.25 | 26 | 26 |
Other Long-Term Liabilities | 30.3 | - | 29.82 | - | - |
Total Liabilities | 2,979 | 2,727 | 2,614 | 2,420 | 1,228 |
Common Stock | 423.1 | 422.47 | 422.47 | 422.47 | 410 |
Additional Paid-In Capital | 1,076 | 982.36 | 1,057 | 1,008 | 738.94 |
Retained Earnings | 1,066 | 1,046 | 897.66 | 743.35 | 555.05 |
Treasury Stock | -20.05 | -10.01 | - | - | - |
Comprehensive Income & Other | -24.21 | -57.82 | -8.64 | 17.77 | -25.8 |
Total Common Equity | 2,521 | 2,383 | 2,369 | 2,192 | 1,678 |
Minority Interest | 325.01 | 42.73 | 48.97 | 50.04 | 63.45 |
Shareholders' Equity | 2,846 | 2,426 | 2,418 | 2,242 | 1,742 |
Total Liabilities & Equity | 5,825 | 5,153 | 5,032 | 4,661 | 2,970 |
Total Debt | 2,395 | 2,236 | 2,207 | 2,022 | 902.42 |
Net Cash (Debt) | -1,433 | -1,470 | -1,158 | -791.15 | -564.82 |
Net Cash Per Share | -3.42 | -3.50 | -2.75 | -1.91 | -1.39 |
Filing Date Shares Outstanding | 422.54 | 422.11 | 422.1 | 422.47 | 410 |
Total Common Shares Outstanding | 422.54 | 422.11 | 422.47 | 422.47 | 410 |
Working Capital | 508.2 | 587.89 | 917.49 | 1,127 | 409.94 |
Book Value Per Share | 5.97 | 5.65 | 5.61 | 5.19 | 4.09 |
Tangible Book Value | 2,442 | 2,291 | 2,267 | 2,103 | 1,590 |
Tangible Book Value Per Share | 5.78 | 5.43 | 5.37 | 4.98 | 3.88 |
Buildings | 745.28 | 728.65 | 261.26 | 273.4 | 104.72 |
Machinery | 1,271 | 1,122 | 704.8 | 318.41 | 287.37 |
Construction In Progress | 1,187 | 1,167 | 1,736 | 1,666 | 1,131 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.